Three-year Follow-up on the Safety and Effectiveness of Rituximab Plus Chemotherapy as First-Line Treatment of Diffuse Large B-Cell Lymphoma and Follicular Lymphoma in Real-World Clinical Settings in China: A Prospective, Multicenter, Noninterventional Study

BACKGROUND: Prospective real-life data on the safety and effectiveness of rituximab in Chinese patients with diffuse large B-cell lymphoma (DLBCL) or follicular lymphoma (FL) are limited. This real-world study aimed to evaluate long-term safety and effectiveness outcomes of rituximab plus chemothera...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Jian-Qiu, Song, Yong-Ping, Su, Li-Ping, Zhang, Ming-Zhi, Li, Wei, Hu, Yu, Zhang, Xiao-Hong, Gao, Yu-Huan, Niu, Zuo-Xing, Feng, Ru, Wang, Wei, Peng, Jie-Wen, Li, Xiao-Lin, Ouyang, Xue-Nong, Wu, Chang-Ping, Zhang, Wei-Jing, Zeng, Yun, Xiao, Zhen, Liang, Ying-Min, Zhuang, Yong-Zhi, Wang, Ji-Shi, Sun, Zi-Min, Bai, Hai, Cui, Tong-Jian, Feng, Ji-Feng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2018
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6071449/
https://www.ncbi.nlm.nih.gov/pubmed/30058572
http://dx.doi.org/10.4103/0366-6999.237401

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6071449/
https://www.ncbi.nlm.nih.gov/pubmed/30058572
http://dx.doi.org/10.4103/0366-6999.237401

Ejemplares similares